Human single-chain antibodies inhibit replication of human immunodeficiency virus type 1 (HIV-1)

AIDS Research and Human Retroviruses

Volumn 21, Issue 10, 2005, Pages 876-881

  Liu, Fangbing ^a   Kumar, Mukesh ^a   Ma, Qiangzhong ^a   Duval, Mark ^a   Kuhrt, David ^a   Junghans, Richard ^a   Posner, Marshall ^a   Cavacini, Lisa ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; EPITOPE; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; ENDOPLASMIC RETICULUM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL; VIRUS ASSEMBLY; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; DNA PRIMERS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MICE; NEUTRALIZATION TESTS; NIH 3T3 CELLS; VIRUS REPLICATION;

EID: 31444440134     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.876     Document Type: Article

References (29)

1. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, and Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312: 763-767.
2. Sodroski J, Goh WC, Rosen C, Campbell K, and Haseltine WA: Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 1986;322:470-474.
3. Lifson, JD, Feinberg MD, Reyes GR, et al.: Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoproteins. Nature 1986;323:725-728.
4. Deng H, Liu R, Ellmeier W, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666.
5. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
6. Choe H, Farzan M, Sun Y, et al.: The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85:1135-1148.
7. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry co-factor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
8. Dorn J, Masciotra S, Yang C, et al.: Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection. J Clin Microbiol 2000;38:773-780.
9. Marasco WA, Haseltine WA, and Chen SY: Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA 1993;90:7889-7893.
10. Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Helland DG, and Marasco WA: Inhibition of HIV-1 tat-mediated LTR transactivation and HIV-1 infection by anti-tat single chain intrabodies. EMBO J 1995;14:1542-1551.
11. ras single chain Fv fragments inhibits meiotic maturation of Xenopus oocytes. Biochem Biophys Res Commun 1993;197:422-427.
12. Duan L, Bagasra O, Laughlin MA, Oakes JW, and Pomerantz RJ: Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-rev single-chain antibody. Proc Natl Acad Sci USA 1994;91:5075-5079.
13. Shaheen F, Duan L, Zhu M, Bagasra O, and Pomerantz RJ: Targeting human immunodeficiency virus type I reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J Virol 1996;70:3392-3400.
14. Maciejewski JP, Weichold FF, Young NS, Cara A, Zella D, Reitz MS Jr, and Gallo RC: Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nat Med 1995;1:667-673.
15. Richardson JH, Sodroski JG, Waldmann TA, and Marasco WA: Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the α subunit of the receptor. Proc Natl Acad Sci USA 1995;92:3137-3141.
16. Beerli RR, Wels W, and Hynes NE: Intracellular expression of single-chain antibodies reverts ErbB-2 transformation. J Biol Chem 1994;269:23931-23936.
17. Deshane J, Loechel F, Conry RM, Siegal GP, King CR, and Curiel DT: Intracellular single-chain antibody directed against ErbB2 down-regulates cell surface ErbB2 and exhibits a selective antiproliferative effect in ErbB2 overexpressing cancer cell lines. Gene Ther 1994;1:332-337.
18. Bilbao G, Contreras JL, and Curiel DT: Genetically engineered intracellular single-chain antibodies in gene therapy. Mol Biotechnol 2002;22:191-211.
19. Richardson JH and Marasco WA: Intracellular antibodies: Development and therapeutic potential. Trends Biotechnol 1995;13:306-310.
20. Zhou P, Goldstein S, Devadas K, Tewari D, and Notkins AL: Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: Targeting the endoplasmic reticulum and trans-Golgi network. J Immunol 1998;160:1489-1496.
21. Cavacini LA, Ernes CL, Wisnewski AV, Power J, Lewis G, Montefiori D, and Posner MR: Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses 1998;14:1271-1280.
22. Miller AD: Cell-surface receptors for retroviruses and implications for gene transfer. Proc Natl Acad Sci USA 1996;93:11407-11413.
23. Miller AD and Chen F: Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry. J Virol 1996;70:5564-5571.
24. Cavacini LA, Ernes CL, Power J, Desharnais FD, Duval M, Montefiori D, and Posner MR: Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody. J Immunol 1995;155:3638-3644.
25. Cavacini LA, Ernes CL, Power J, Duval M, and Posner MR: Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization. J Immunol 1994;152:2538-2545.
26. Cavacini LA, Emes CL, Power J, Buchbinder A, Zolla-Pazner S, and Posner MR: Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. J Acquir Immune Defic Syndr 1993; 6:353-358.
27. Cavacini LA, Duval M, Robinson J, and Posner MR: Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions. AIDS 2002;16: 2409-2417.
28. Lee SJ, Garza L, Yao J, Notkins AL, and Zhou P: A nonneutralizing anti-HIV-1 antibody turns into a neutralizing antibody when expressed on the surface of HIV-1-susceptible cells: A new way to fight HIV. J Immunol 2004;173:4618-4626.
29. Biocca S, Ruberti F, Tafani M, Pierandrei-Amladi P, and Cattaneo A: Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol and mitochondria. BioTechniques 1995;13:1110-1115.